Cellectis S.A. (NASDAQ:CLLS) Sees Large Growth in Short Interest

Cellectis S.A. (NASDAQ:CLLS) saw a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 221,300 shares, a growth of 34.0% from the January 15th total of 165,200 shares. Based on an average daily volume of 139,900 shares, the days-to-cover ratio is currently 1.6 days.

Institutional Investors Weigh In On Cellectis

An institutional investor recently raised its position in Cellectis stock. Wells Fargo & Company MN boosted its holdings in Cellectis S.A. (NASDAQ:CLLS) by 103.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,590 shares of the biotechnology company’s stock after buying an additional 12,500 shares during the quarter. Wells Fargo & Company MN’s holdings in Cellectis were worth $44,000 at the end of the most recent reporting period. 63.90% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

CLLS has been the topic of several research analyst reports. Barclays dropped their price objective on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th. StockNews.com started coverage on shares of Cellectis in a research note on Friday, January 24th. They issued a “buy” rating on the stock.

Cellectis Stock Up 1.3 %

Shares of CLLS traded up $0.02 during mid-day trading on Friday, reaching $1.55. The company had a trading volume of 77,558 shares, compared to its average volume of 167,729. The company’s 50 day simple moving average is $1.66 and its 200 day simple moving average is $1.93. Cellectis has a 1-year low of $1.41 and a 1-year high of $3.38. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.